^
Association details:
Biomarker:BIRC3 mutation
Cancer:Chronic Lymphocytic Leukemia
Drug:DC-1-192 (NF-κB inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-?B activity and synergise with bortezomib and ibrutinib in hematological cancers

Published date:
04/01/2021
Excerpt:
In primary CLL cells, sensitivity to DC-1-192 was inversely correlated with RelA subunit expression (r2=0.2) and samples with BIRC3 or NOTCH1 mutations showed increased sensitivity (P=0.001).
DOI:
10.3324/haematol.2019.238584